Clemastine
Sponsors
Universitaet Muenster, Bioinvent International AB, Poltreg S.A., Novartis, University of California, San Francisco
Conditions
Advanced breast cancerAdvanced solid tumorsChronic UrticariaEfficacy and SafetyEwing sarcomaMultiple Sclerosis, Relapsing-RemittingNeuroblastomaOptic Neuritis
Phase 1
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First in-Human, Consecutive-Cohort, Clinical Trial of BI 1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
CompletedCTIS2022-503066-74-00
Start: 2023-12-04End: 2025-12-17Target: 186Updated: 2025-10-07
A phase I safety, dose finding and feasibility trial of GD2IL18CART in patients with relapsed or refractory GD2 positive solid cancers
RecruitingCTIS2022-501725-21-00
Start: 2024-04-12Target: 48Updated: 2025-10-17
Phase 2
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
CompletedNCT00481676
Start: 2007-05-31End: 2009-04-30Updated: 2011-10-21
Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis
CompletedNCT02040298
Start: 2014-01-31End: 2016-04-30Updated: 2025-09-17
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
RecruitingNCT02521311
Start: 2017-02-28End: 2028-08-01Target: 90Updated: 2026-03-11
A multicenter, randomized, blinded, placebo controlled, phase II study to evaluate the safety and efficacy of cell therapy based with artificially expanded CD4+CD25+CD127- regulatory lymphocytes and anti-CD20 antibody in pediatric patients with presymptomatic diabetes type 1 (stage 1)
RecruitingCTIS2023-505226-33-00
Start: 2025-01-28Target: 150Updated: 2025-08-01